Cargando…

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study

Precision medicine aims to treat an individual based on their clinical characteristics. A differential drug response, critical to using these features for therapy selection, has never been examined directly in type 2 diabetes. We tested two hypotheses: 1) individuals with BMI>30kg/m(2), compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shields, Beverley M, Dennis, John M, Angwin, Catherine D, Warren, Fiona, Henley, William E, Farmer, Andrew J, Sattar, Naveed, Holman, Rury R, Jones, Angus G, Pearson, Ewan R, Hattersley, Andrew T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614216/ https://www.ncbi.nlm.nih.gov/pubmed/36477733 http://dx.doi.org/10.1038/s41591-022-02120-7

Ejemplares similares

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
por: Angwin, Catherine, et al.
Publicado: (2020)

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
por: Dennis, John M., et al.
Publicado: (2019)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
por: Jones, Angus G., et al.
Publicado: (2016)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach
por: Dennis, John M, et al.
Publicado: (2018)

Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes
por: Rodgers, Lauren R, et al.
Publicado: (2017)

Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine
por: Jones, Angus G., et al.
Publicado: (2014)

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
por: Dennis, John M, et al.
Publicado: (2019)

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Identifying routine clinical predictors of non‐adherence to second‐line therapies in type 2 diabetes: A retrospective cohort analysis in a large primary care database
por: Shields, Beverley M., et al.
Publicado: (2019)

Response to Comment on: Besser et al. Lessons From the Mixed-Meal Tolerance Test: Use of 90-Minute and Fasting C-Peptide in Pediatric Diabetes. Diabetes Care 2013;36:195–201
por: Shields, Beverley M., et al.
Publicado: (2013)

Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years
por: Lynam, Anita, et al.
Publicado: (2019)

Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
por: Dakin, Helen A., et al.
Publicado: (2020)

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin
por: Shepherd, Maggie H., et al.
Publicado: (2018)

Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial: An interview study of patients' and health professionals' experiences
por: Jenkins, Nicholas, et al.
Publicado: (2010)

Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study
por: Rodgers, Lauren R., et al.
Publicado: (2020)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Unravelling the Heterogeneity of Non Insulin Dependent Diabetes
por: Pearson, Ewan R, et al.
Publicado: (2000)

Strategies to identify individuals with monogenic diabetes: results of an economic evaluation
por: Peters, Jaime L, et al.
Publicado: (2020)

Mastering the roll: succeeding amidst change means trying new things, failing, and trying more
por: Shea, Gregory P, et al.
Publicado: (2010)

Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
por: Lawton, Julia, et al.
Publicado: (2011)

Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters
por: Knight, Bridget A, et al.
Publicado: (2016)

Assessment of the HNF1B Score as a Tool to Select Patients for HNF1B Genetic Testing
por: Clissold, Rhian, et al.
Publicado: (2015)

Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine
por: Venkatasubramaniam, Ashwini, et al.
Publicado: (2023)

Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies
por: Greiner, Rosamund, et al.
Publicado: (2021)

Meeting report of the third annual Tri-Service Microbiome Consortium symposium
por: Karl, J. Philip, et al.
Publicado: (2020)

The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
por: Young, Katherine G., et al.
Publicado: (2022)

Correction to: The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
por: Young, Katherine G., et al.
Publicado: (2023)

Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2011)

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin
por: Jones, Angus G, et al.
Publicado: (2012)

Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017
por: Curtis, Helen J., et al.
Publicado: (2018)

Lessons From the Mixed-Meal Tolerance Test: Use of 90-minute and fasting C-peptide in pediatric diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2013)

Five-Year Follow-Up for Women With Subclinical Hypothyroidism in Pregnancy
por: Shields, Beverley M., et al.
Publicado: (2013)

Response to Comment on: Chakera et al. Antenatal Diagnosis of Fetal Genotype Determines if Maternal Hyperglycemia due to a Glucokinase Mutation Requires Treatment. Diabetes Care 2012;35:1832–1834
por: Chakera, Ali J., et al.
Publicado: (2013)

Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia
por: Hope, Suzy V., et al.
Publicado: (2018)

The effect of a brief action planning intervention on adherence to double-blind study medication compared to a standard trial protocol in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study
por: Farmer, Andrew J., et al.
Publicado: (2016)

Assessing newborn body composition using principal components analysis: differences in the determinants of fat and skeletal size
por: Shields, Beverley M, et al.
Publicado: (2006)

Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature
por: Shields, Beverley M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rb78qg1c1ntpsvrab3m7855mb3